CCO Treatment Updates
Weighing the Options: Choosing the Initial Antiretroviral Regimen
Weighing the Options for First-line Antiretroviral Therapy |
Module 1 of 2 |
|
Program Director: Joseph J. Eron, Jr., MD
- Edwin DeJesus, MD, FACP, AAHIVS
|
|
|
Edwin DeJesus, MD, FACP, AAHIVS, discusses clinical trial information to help participants weigh the options for choosing first-line antiretroviral therapy.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Cite patient and drug factors that should be considered when planning first-line antiretroviral therapy
- Explain the preferred choices for first-line therapy as denoted by US treatment guidelines
- Discuss the data supporting the use of efavirenz as a first-line option with 2 NRTIs, including considerations regarding the choice between NNRTI-based and PI-based initial therapy
- Describe the advantages and disadvantages of the various boosted PI regimens recommended by the US treatment guidelines
- Recount factors influencing the choice between tenofovir/emtricitabine and abacavir/lamivudine in first-line regimens
Abstract
|
First-line Antiretroviral Therapy: Finding the Right Fit |
Module 2 of 2 |
|
Program Director: Joseph J. Eron, Jr., MD
|
|
David A. Wohl, MD, discusses critical factors involved in choosing an initial antiretroviral regimen for individual patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss how current guidelines can be used to formulate individualized treatment regimens for antiretroviral-naive HIV-infected patients
- Recount baseline factors that might be relevant in the individualization of initial antiretroviral regimens
- Describe cohort and clinical trial data that might be used to make individualized treatment decisions for antiretroviral-naive patients
- Explain when conventional regimens may not be the best choices for certain individual patients
Abstract
|
Interactive Virtual Presentation
Weighing the Options for First-Line Antiretroviral Therapy
|
|
|
Participate in case management decisions with Joseph J. Eron, Jr., MD, as he reviews the most pertinent clinical issues regarding the initial selection of antiretroviral treatment for patients infected with HIV-1.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Apply recent clinical trial data comparing NNRTI- vs PI-based regimens when selecting initial therapy for HIV-infected patients
- Differentiate between boosted PIs based on efficacy, adverse effects, dosing convenience, and potential drug-drug interactions
- Describe individual patient cases in which abacavir/lamivudine may be preferable to tenofovir/emtricitabine and vice versa
- Summarize recent data on the efficacy, safety, and resistance profile of novel classes for the initial treatment of HIV infection
Abstract
|
Slideset: Weighing the Options for First-line Antiretroviral Therapy
 |
|
Joseph J. Eron, Jr., MD, challenges the participants with data that should be considered when choosing an initial antiretroviral regimen for a treatment-naive patient.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.22 MB
| Date posted: 7/9/2009
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|